Tosymra Approved to Treat Migraines
January 27, 2019 – The U.S. FDA has approved Tosymra™ (sumatriptan nasal spray) 10mg, manufactured by Promius Pharma (a U.S. subsidiary of Dr. Reddy’s), to provide acute treatment for adults who experience migraine headaches with or without an aura.
Although other forms of sumatriptan exist on the U.S. market, Tosymra uses a novel formulation to provide a rapid onset of action. Recommended dosing is one 10mg spray in one nostril. Patients can take up to two additional doses, with each dose at least one hour apart, within a 24-hour period if needed. Tosymra should not be used to prevent migraines or to treat cluster headaches. It is not interchangeable with other sumatriptan products, including GlaxoSmithKline’s Imitrex® (sumatriptan nasal spray) and AVANIR Pharmaceuticals’ Onzetra Xsail® (sumatriptan nasal powder for inhalation).
Promius has not yet announced launch or pricing plans.